EGFR-targeted therapy plus immunotherapy for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests combining two types of cancer drugs—a targeted pill that attacks a specific mutation in your lung cancer cells, followed by an immunotherapy injection when your tumor stops shrinking. The goal is to see if this combination works better than standard treatment alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Advanced or metastatic non-small cell lung cancer (NSCLC) with an EGFR mutation (specifically 19del or L858R)
- Never received immunotherapy (PD-1 or PD-L1 drugs) before
- Age 18 or older with good overall health and physical function
- No severe lung, heart, liver, or kidney disease, and no active infections
- Not taking immunosuppressive drugs or steroids in the past 2 weeks
- Willing to use effective birth control if you can have children
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding chemotherapy and an immunotherapy drug (sintilimab) to targeted therapy (limertinib) before surgery works better than continuing targeted therapy alone. It is for people with stage II-IIIB EGFR-mutant lung cancer that can be removed with surgery.
This trial tests a combination of pembrolizumab (an immunotherapy) and chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a specific EGFR mutation (exon 21) and a PD-L1 score of 1% or higher. It aims to see if this combination can help shrink tumors and improve outcomes for those who have not yet received any anticancer treatment.
This trial tests giving tumor-fighting immune cells (TILs) with a targeted therapy pill to people with a specific type of lung cancer (EGFR-mutant NSCLC) that stopped responding to previous targeted treatment. The goal is to see if this combination can shrink or control the cancer again.
This trial tests whether adding radiation therapy to a drug combination can help people with a specific type of lung cancer that has stopped responding to standard first-line pills. It's for patients whose cancer has a certain gene change (EGFR) and has spread to other parts of the body.
This trial is testing a combination of immunotherapy and targeted radiation for people with advanced lung cancer that has no targetable gene changes. The goal is to see if adjusting radiation based on how well the tumor responds can improve outcomes.
This trial tests whether giving chemotherapy followed by an immunotherapy drug (sintilimab) before surgery helps people with a specific type of lung cancer (EGFR-mutant, non-small cell) that is at a stage where surgery can be considered. The goal is to improve outcomes by shrinking the tumor before the operation.
Hear when a new Lung Cancer Non-Small Cell Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.